(4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid multiple interactions ISO RGD:1317959 6480464 zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin], zopolrestat inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 (4-oxo-3-\{[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl\}-3,4-dihydrophthalazin-1-yl)acetic acid decreases activity ISO RGD:1317959 6480464 zopolrestat results in decreased activity of AKR1B10 protein, zopolrestat results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 (E)-cinnamyl alcohol increases expression ISO RGD:1317959 6480464 cinnamyl alcohol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 (E,E)-2,4-hexadienal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 2 more ... CTD PMID:21329684 (R)-acetoin increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Acetoin CTD PMID:23295224 (R)-acetoin multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2 more ... CTD PMID:23295224 1,2-dimethylhydrazine increases expression ISO RGD:1317960 6480464 1, 2-Dimethylhydrazine results in increased expression of AKR1B10 mRNA CTD PMID:22206623 1-chloro-2,4-dinitrobenzene increases expression ISO RGD:1317959 6480464 Dinitrochlorobenzene results in increased expression of AKR1B10 mRNA CTD PMID:20566472 13-dihydrodaunorubicin multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol CTD PMID:19028477 17beta-estradiol decreases expression ISO RGD:1317959 6480464 Estradiol results in decreased expression of AKR1B10 mRNA CTD PMID:25321415 17beta-estradiol multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of AKR1B10 mRNA CTD PMID:26496021 17beta-estradiol multiple interactions ISO RGD:1317959 6480464 [Estradiol co-treated with TGFB1 protein] results in decreased expression of AKR1B10 mRNA, [Progesterone co-treated with Estradiol] results in decreased expression of AKR1B10 mRNA CTD PMID:17404688 , PMID:30165855 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1317959 6480464 Tetrachlorodibenzodioxin results in increased expression of AKR1B10 mRNA CTD PMID:20106945 more ... 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of AKR1B10 mRNA CTD PMID:33387578 2-(chloromethyl)pyridine increases expression ISO RGD:1317959 6480464 2-chloromethylpyridine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 2-acetamidofluorene multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of AKR1B10 mRNA CTD PMID:14656948 2-acetamidofluorene increases expression ISO RGD:1317959 6480464 2-Acetylaminofluorene results in increased expression of AKR1B10 mRNA CTD PMID:26198647 2-hexenal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 2-hexenal, AKR1B10 protein results in increased reduction of 2-hexenal metabolite CTD PMID:21329684 2-hydroxypropanoic acid increases expression ISO RGD:1317959 6480464 Lactic Acid results in increased expression of AKR1B10 mRNA CTD PMID:20566472 2-hydroxypropanoic acid decreases expression ISO RGD:1317959 6480464 Lactic Acid results in decreased expression of AKR1B10 mRNA CTD PMID:30851411 2-tert-butylhydroquinone increases expression ISO RGD:1317959 6480464 2-tert-butylhydroquinone results in increased expression of AKR1B10 mRNA CTD PMID:30806763 3-chloropropane-1,2-diol increases expression EXP 6480464 alpha-Chlorohydrin results in increased expression of AKR1B10 mRNA CTD PMID:28522335 3-Hydroxybenzo[a]pyrene increases expression ISO RGD:1317959 6480464 3-hydroxybenzo(a)pyrene results in increased expression of AKR1B10 mRNA CTD PMID:26238291 3-methyl-3H-imidazo[4,5-f]quinolin-2-amine decreases expression ISO RGD:1317959 6480464 2-amino-3-methylimidazo(4, 5-f)quinoline results in decreased expression of AKR1B10 mRNA CTD PMID:26198647 3-phenylprop-2-enal increases expression ISO RGD:1317959 6480464 cinnamaldehyde results in increased expression of AKR1B10 mRNA CTD PMID:30806763 4,4'-methylene-bis-(2-chloroaniline) increases expression ISO RGD:1317959 6480464 Methylenebis(chloroaniline) results in increased expression of AKR1B10 mRNA CTD PMID:26198647 4,4'-sulfonyldiphenol increases expression ISO RGD:1317960 6480464 bis(4-hydroxyphenyl)sulfone results in increased expression of AKR1B10 mRNA CTD PMID:30951980 4-hydroperoxycyclophosphamide affects response to substance ISO RGD:1317959 6480464 AKR1B10 protein affects the susceptibility to perfosfamide CTD PMID:18473730 4-hydroxynon-2-enal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 4-hydroxy-2-nonenal CTD PMID:19013440 , PMID:21329684 4-hydroxynon-2-enal increases metabolic processing ISO RGD:1317959 6480464 AKR1B10 protein results in increased metabolism of 4-hydroxy-2-nonenal CTD PMID:27417252 4-hydroxynon-2-enal multiple interactions ISO RGD:1317959 6480464 Oleanolic Acid inhibits the reaction [AKR1B10 protein results in increased metabolism of 4-hydroxy-2-nonenal] CTD PMID:27417252 4-hydroxyphenyl retinamide increases expression ISO RGD:1317960 6480464 Fenretinide results in increased expression of AKR1B10 mRNA CTD PMID:28973697 4-methylpentanal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of isocaproaldehyde CTD PMID:19013440 4-nitro-1,2-phenylenediamine increases expression ISO RGD:1317959 6480464 1, 2-diamino-4-nitrobenzene results in increased expression of AKR1B10 mRNA CTD PMID:26198647 5-fluorouracil affects expression ISO RGD:1317959 6480464 Fluorouracil affects the expression of AKR1B10 mRNA CTD PMID:16584549 7,12-dimethyltetraphene increases expression ISO RGD:1317959 6480464 9 more ... CTD PMID:26198647 9,10-phenanthroquinone increases expression ISO RGD:1317959 6480464 9, 10-phenanthrenequinone results in increased expression of AKR1B10 mRNA CTD PMID:24813866 9,10-phenanthroquinone increases metabolic processing ISO RGD:1317959 6480464 AKR1B10 protein results in increased metabolism of 9, 10-phenanthrenequinone CTD PMID:24813866 9-cis-retinal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 9-cis-retinal CTD PMID:21851338 [6]-Shogaol increases expression ISO RGD:1317959 6480464 shogaol metabolite results in increased expression of AKR1B10 protein more ... CTD PMID:25148906 acetoin increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Acetoin CTD PMID:23295224 acetoin multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2 more ... CTD PMID:23295224 acrolein affects metabolic processing ISO RGD:1317959 6480464 Acrolein affects the metabolism of AKR1B10 protein, AKR1B10 protein affects the metabolism of Acrolein CTD PMID:17329238 , PMID:17597105 acrolein increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Acrolein, AKR1B10 protein results in increased reduction of Acrolein metabolite CTD PMID:21329684 acrolein decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to Acrolein CTD PMID:17329238 , PMID:17597105 aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of AKR1B10 mRNA CTD PMID:23630614 , PMID:25378103 aflatoxin B1 increases expression ISO RGD:1317959 6480464 Aflatoxin B1 results in increased expression of AKR1B10 mRNA CTD PMID:32234424 all-trans-4-oxoretinal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 4-oxoretinaldehyde CTD PMID:19014918 all-trans-dehydroretinal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of dehydroretinal CTD PMID:19014918 all-trans-retinal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Retinaldehyde CTD PMID:19014918 all-trans-retinal increases metabolic processing ISO RGD:1317959 6480464 AKR1B10 protein results in increased metabolism of Retinaldehyde CTD PMID:21329680 all-trans-retinol decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to Vitamin A, AKR1B10 protein results in decreased susceptibility to Vitamin A metabolite CTD PMID:19014918 Aloe emodin decreases activity ISO RGD:1317959 6480464 aloe emodin results in decreased activity of AKR1B10 protein CTD PMID:35065925 alpha-hexylcinnamaldehyde increases expression ISO RGD:1317959 6480464 hexyl cinnamic aldehyde results in increased expression of AKR1B10 mRNA CTD PMID:20566472 amoxicillin increases expression ISO RGD:1317959 6480464 Amoxicillin results in increased expression of AKR1B10 mRNA CTD PMID:28444390 ampicillin decreases expression ISO RGD:1317959 6480464 Ampicillin results in decreased expression of AKR1B10 mRNA CTD PMID:21632981 , PMID:26198647 anthranilic acid increases expression ISO RGD:1317959 6480464 anthranilic acid results in increased expression of AKR1B10 mRNA CTD PMID:26198647 antimonite multiple interactions ISO RGD:1317959 6480464 [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 arsane multiple interactions ISO RGD:1317959 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1B10 mRNA CTD PMID:32525701 arsenic atom multiple interactions ISO RGD:1317959 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1B10 mRNA CTD PMID:32525701 arsenite(3-) multiple interactions ISO RGD:1317959 6480464 [sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 arsenous acid decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to Arsenic Trioxide CTD PMID:20707922 Augmentin increases expression ISO RGD:1317959 6480464 Amoxicillin-Potassium Clavulanate Combination results in increased expression of AKR1B10 mRNA CTD PMID:34767876 azathioprine increases expression ISO RGD:1317959 6480464 Azathioprine results in increased expression of AKR1B10 mRNA CTD PMID:22623647 , PMID:26198647 Bandrowski's base increases expression ISO RGD:1317959 6480464 Bandrowski's base results in increased expression of AKR1B10 mRNA CTD PMID:20566472 benzalkonium chloride increases expression ISO RGD:1317959 6480464 Benzalkonium Compounds results in increased expression of AKR1B10 mRNA CTD PMID:30806763 benzidine increases expression ISO RGD:1317959 6480464 benzidine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of AKR1B10 mRNA CTD PMID:21839799 benzo[a]pyrene increases methylation ISO RGD:1317959 6480464 Benzo(a)pyrene results in increased methylation of AKR1B10 promoter CTD PMID:27901495 benzo[a]pyrene affects methylation ISO RGD:1317959 6480464 Benzo(a)pyrene affects the methylation of AKR1B10 exon CTD PMID:27901495 benzo[a]pyrene increases expression ISO RGD:1317960 6480464 Benzo(a)pyrene results in increased expression of AKR1B10 mRNA CTD PMID:19770486 benzo[a]pyrene increases expression ISO RGD:1317959 6480464 Benzo(a)pyrene results in increased expression of AKR1B10 mRNA, Benzo(a)pyrene results in increased expression of AKR1B10 protein CTD PMID:16545412 more ... Benzo[a]pyrene-7,8-diol multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein co-treated with NADP] results in increased oxidation of and affects the activity of benzo(a)pyrene 7, 8-dihydrodiol CTD PMID:21910479 benzo[a]pyrene-7,8-dione multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7, 8-dione CTD PMID:21910479 benzoic acid increases expression ISO RGD:1317959 6480464 Benzoic Acid results in increased expression of AKR1B10 mRNA CTD PMID:20566472 bis(2-chloroethyl) sulfide increases expression ISO RGD:1317959 6480464 Mustard Gas results in increased expression of AKR1B10 mRNA CTD PMID:25102026 bis(2-ethylhexyl) phthalate increases expression ISO RGD:1317959 6480464 Diethylhexyl Phthalate results in increased expression of AKR1B10 mRNA CTD PMID:28412506 bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with Estradiol] results in increased expression of AKR1B10 mRNA CTD PMID:26496021 bisphenol A increases expression EXP 6480464 bisphenol A results in increased expression of AKR1B10 mRNA CTD PMID:30816183 bisphenol A affects expression ISO RGD:1317959 6480464 bisphenol A affects the expression of AKR1B10 mRNA CTD PMID:30903817 bisphenol A increases methylation EXP 6480464 bisphenol A results in increased methylation of AKR1B10 gene CTD PMID:28505145 bisphenol A multiple interactions ISO RGD:1317960 6480464 [potassium bromate co-treated with bisphenol A] affects the expression of AKR1B10 mRNA, [XRCC6 gene mutant form results in increased susceptibility to potassium bromate] affects the reaction [[potassium bromate co-treated with bisphenol A] affects the expression of AKR1B10 mRNA] CTD PMID:27082013 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of AKR1B10 mRNA CTD PMID:25181051 bortezomib increases expression ISO RGD:1317959 6480464 Bortezomib results in increased expression of AKR1B10 mRNA, Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 butane-2,3-diol multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of Acetoin] which results in increased chemical synthesis of 2, 3-butylene glycol CTD PMID:23295224 butane-2,3-dione increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Diacetyl CTD PMID:23295224 butane-2,3-dione multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of Diacetyl] which results in increased chemical synthesis of Acetoin CTD PMID:23295224 cadmium atom increases expression ISO RGD:1317959 6480464 Cadmium results in increased expression of AKR1B10 mRNA CTD PMID:21120746 , PMID:21172416 cadmium sulfate multiple interactions ISO RGD:1317959 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1B10 mRNA CTD PMID:18654764 captan increases expression ISO RGD:1317960 6480464 Captan results in increased expression of AKR1B10 mRNA CTD PMID:31558096 carbamazepine affects expression ISO RGD:1317959 6480464 Carbamazepine affects the expression of AKR1B10 mRNA CTD PMID:25979313 carbon nanotube decreases expression ISO RGD:1317960 6480464 Nanotubes more ... CTD PMID:25554681 chlorambucil decreases expression ISO RGD:1317959 6480464 Chlorambucil results in decreased expression of AKR1B10 mRNA CTD PMID:26198647 chrysin decreases expression ISO RGD:1317959 6480464 chrysin results in decreased expression of AKR1B10 mRNA, chrysin results in decreased expression of AKR1B10 protein CTD PMID:23994249 cinnamyl alcohol increases expression ISO RGD:1317959 6480464 cinnamyl alcohol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 ciprofibrate multiple interactions ISO RGD:1317959 6480464 ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin], ciprofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 ciprofibrate decreases activity ISO RGD:1317959 6480464 ciprofibrate results in decreased activity of AKR1B10 protein, ciprofibrate results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 cisplatin increases expression ISO RGD:1317959 6480464 Cisplatin results in increased expression of AKR1B10 mRNA CTD PMID:19561079 , PMID:27392435 cisplatin multiple interactions ISO RGD:1317959 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of AKR1B10 mRNA CTD PMID:27392435 cisplatin decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to Cisplatin CTD PMID:27417252 clavulanic acid increases expression ISO RGD:1317959 6480464 Clavulanic Acid results in increased expression of AKR1B10 mRNA CTD PMID:34767876 Clofop multiple interactions ISO RGD:1317959 6480464 fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin], fenofibric acid inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 Clofop decreases activity ISO RGD:1317959 6480464 fenofibric acid results in decreased activity of AKR1B10 protein, fenofibric acid results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 cobalt dichloride multiple interactions ISO RGD:1317959 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1B10 mRNA CTD PMID:18654764 copper atom multiple interactions ISO RGD:1317959 6480464 [NSC 689534 binds to Copper] which results in increased expression of AKR1B10 mRNA CTD PMID:20971185 copper(0) multiple interactions ISO RGD:1317959 6480464 [NSC 689534 binds to Copper] which results in increased expression of AKR1B10 mRNA CTD PMID:20971185 copper(II) sulfate increases expression ISO RGD:1317959 6480464 Copper Sulfate results in increased expression of AKR1B10 mRNA CTD PMID:19549813 crotonaldehyde affects metabolic processing ISO RGD:1317959 6480464 2-butenal affects the metabolism of AKR1B10 protein CTD PMID:17597105 crotonaldehyde decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to 2-butenal CTD PMID:17597105 crotonaldehyde increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 2-butenal, AKR1B10 protein results in increased reduction of 2-butenal metabolite CTD PMID:21329684 cyclosporin A increases expression ISO RGD:1317959 6480464 Cyclosporine results in increased expression of AKR1B10 mRNA CTD PMID:25562108 cyclosporin A decreases expression ISO RGD:1317959 6480464 Cyclosporine results in decreased expression of AKR1B10 mRNA CTD PMID:27989131 D-glyceraldehyde multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 , PMID:19028477 D-glyceraldehyde increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Glyceraldehyde CTD PMID:19014918 , PMID:19028477 D-glyceraldehyde increases metabolic processing ISO RGD:1317959 6480464 AKR1B10 protein results in increased metabolism of Glyceraldehyde CTD PMID:18325492 daunorubicin decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to Daunorubicin CTD PMID:19028477 daunorubicin increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Daunorubicin CTD PMID:19028477 daunorubicin multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of Daunorubicin] which results in increased chemical synthesis of daunorubicinol more ... CTD PMID:19028477 DDT increases expression ISO RGD:1317959 6480464 DDT results in increased expression of AKR1B10 mRNA CTD PMID:26198647 diarsenic trioxide decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to Arsenic Trioxide CTD PMID:20707922 dibenzo[a,l]pyrene decreases expression ISO RGD:1317959 6480464 dibenzo(a, l)pyrene results in decreased expression of AKR1B10 mRNA CTD PMID:31255691 diethyl maleate increases expression ISO RGD:1317959 6480464 diethyl maleate results in increased expression of AKR1B10 mRNA CTD PMID:33545341 diethylstilbestrol increases expression ISO RGD:1317959 6480464 Diethylstilbestrol results in increased expression of AKR1B10 mRNA CTD PMID:26198647 dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate increases expression ISO RGD:1317959 6480464 Antimony Potassium Tartrate results in increased expression of AKR1B10 mRNA CTD PMID:28713220 dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate multiple interactions ISO RGD:1317959 6480464 [Antimony Potassium Tartrate results in increased abundance of antimonite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 diquat increases expression ISO RGD:1317959 6480464 Diquat results in increased expression of AKR1B10 mRNA CTD PMID:21172416 disulfiram increases expression ISO RGD:1317959 6480464 Disulfiram results in increased expression of AKR1B10 mRNA CTD PMID:20566472 dorsomorphin multiple interactions ISO RGD:1317959 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1B10 mRNA CTD PMID:27188386 doxorubicin multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA more ... CTD PMID:25686905 doxorubicin increases expression ISO RGD:1317959 6480464 Doxorubicin results in increased expression of AKR1B10 mRNA CTD PMID:29803840 doxorubicin decreases response to substance ISO RGD:1317959 6480464 AKR1B10 protein results in decreased susceptibility to Doxorubicin CTD PMID:25686905 emodin decreases activity ISO RGD:1317959 6480464 Emodin results in decreased activity of AKR1B10 protein CTD PMID:35065925 ethanol affects expression ISO RGD:1317960 6480464 Ethanol affects the expression of AKR1B10 mRNA CTD PMID:30319688 ethoxyquin increases expression ISO RGD:1317959 6480464 Ethoxyquin results in increased expression of AKR1B10 mRNA CTD PMID:21277289 ethoxyquin multiple interactions ISO RGD:1317959 6480464 NFE2L2 protein promotes the reaction [Ethoxyquin results in increased expression of AKR1B10 mRNA] CTD PMID:21277289 Ethyl 1-benzyl-3-hydroxy- 2-oxo[5H]pyrrole-4-carboxylate decreases activity ISO RGD:1317959 6480464 ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate results in decreased activity of AKR1B10 protein CTD PMID:18325492 Ethyl 1-benzyl-3-hydroxy- 2-oxo[5H]pyrrole-4-carboxylate multiple interactions ISO RGD:1317959 6480464 ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin], ethyl 1-benzyl-3-hydroxy-2(5H)-oxopyrrole-4-carboxylate inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 Ethyl acrylate increases expression ISO RGD:1317959 6480464 ethyl acrylate results in increased expression of AKR1B10 mRNA CTD PMID:26198647 eugenol increases expression ISO RGD:1317959 6480464 Eugenol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 more ... farnesal increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of farnesal CTD PMID:21187079 farnesol increases chemical synthesis ISO RGD:1317959 6480464 AKR1B10 protein results in increased chemical synthesis of Farnesol CTD PMID:21187079 fenofibrate multiple interactions ISO RGD:1317959 6480464 Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin], Fenofibrate inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 fenofibrate decreases activity ISO RGD:1317959 6480464 Fenofibrate results in decreased activity of AKR1B10 protein, Fenofibrate results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 Fidarestat affects binding ISO RGD:1317959 6480464 NADP binds to AKR1B10 protein mutant form binds to fidarestat CTD PMID:23295227 Fidarestat multiple interactions ISO RGD:1317959 6480464 fidarestat binds to and results in decreased activity of AKR1B10 protein mutant form CTD PMID:23295227 flucloxacillin increases expression ISO RGD:1317959 6480464 Floxacillin results in increased expression of AKR1B10 mRNA CTD PMID:28444390 folpet increases expression ISO RGD:1317960 6480464 folpet results in increased expression of AKR1B10 mRNA CTD PMID:31558096 formaldehyde decreases expression ISO RGD:1317959 6480464 Formaldehyde results in decreased expression of AKR1B10 mRNA CTD PMID:27664576 Frangulin A decreases activity ISO RGD:1317959 6480464 frangulin A results in decreased activity of AKR1B10 protein CTD PMID:35065925 Frangulin B decreases activity ISO RGD:1317959 6480464 frangulin B results in decreased activity of AKR1B10 protein CTD PMID:35065925 furan increases expression EXP 6480464 furan results in increased expression of AKR1B10 mRNA CTD PMID:25539665 gemfibrozil decreases activity ISO RGD:1317959 6480464 Gemfibrozil results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of AKR1B10 mRNA CTD PMID:33387578 geranylgeraniol increases chemical synthesis ISO RGD:1317959 6480464 AKR1B10 protein results in increased chemical synthesis of geranylgeraniol CTD PMID:21187079 glyceraldehyde multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 , PMID:19028477 glyceraldehyde increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of Glyceraldehyde CTD PMID:19014918 , PMID:19028477 glyceraldehyde increases metabolic processing ISO RGD:1317959 6480464 AKR1B10 protein results in increased metabolism of Glyceraldehyde CTD PMID:18325492 gold atom increases expression ISO RGD:1317959 6480464 Gold results in increased expression of AKR1B10 mRNA CTD PMID:29705079 gold(0) increases expression ISO RGD:1317959 6480464 Gold results in increased expression of AKR1B10 mRNA CTD PMID:29705079 hexane increases expression ISO RGD:1317959 6480464 n-hexane results in increased expression of AKR1B10 mRNA CTD PMID:20566472 hexane-2,3-dione multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of 2, 3-hexanedione] which results in increased chemical synthesis of Hexanones CTD PMID:23295224 hexane-2,3-dione increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 2, 3-hexanedione CTD PMID:23295224 hydrogen peroxide affects expression ISO RGD:1317959 6480464 Hydrogen Peroxide affects the expression of AKR1B10 mRNA CTD PMID:23410634 hydroquinone decreases expression ISO RGD:1317959 6480464 hydroquinone results in decreased expression of AKR1B10 mRNA CTD PMID:31256213 indan-1-ol increases oxidation ISO RGD:1317959 6480464 AKR1B10 protein results in increased oxidation of 1-indanol CTD PMID:19013440 isoeugenol increases expression ISO RGD:1317959 6480464 isoeugenol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 isoniazide increases expression ISO RGD:1317959 6480464 Isoniazid results in increased expression of AKR1B10 mRNA CTD PMID:28444390 Isoxanthohumol decreases activity ISO RGD:1317959 6480464 isoxanthohumol results in decreased activity of AKR1B10 protein CTD PMID:35065925 L-ascorbic acid increases expression ISO RGD:1317959 6480464 Ascorbic Acid results in increased expression of AKR1B10 mRNA CTD PMID:26198647 lead(II) chloride multiple interactions ISO RGD:1317959 6480464 [cadmium sulfate co-treated with cobaltous chloride co-treated with lead chloride] results in increased expression of AKR1B10 mRNA CTD PMID:18654764 lead(II) chloride increases expression ISO RGD:1317959 6480464 lead chloride results in increased expression of AKR1B10 mRNA CTD PMID:18654764 Licochalcone B increases expression ISO RGD:1317959 6480464 licochalcone B results in increased expression of AKR1B10 mRNA CTD PMID:33647349 lipopolysaccharide increases expression ISO RGD:1317959 6480464 Lipopolysaccharides results in increased expression of AKR1B10 mRNA CTD PMID:35811015 lipopolysaccharide multiple interactions ISO RGD:1317959 6480464 [S-(1 more ... CTD PMID:35811015 LY294002 decreases expression ISO RGD:1317959 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKR1B10 protein CTD PMID:23994249 menadione increases expression ISO RGD:1317959 6480464 Vitamin K 3 results in increased expression of AKR1B10 mRNA CTD PMID:23410634 , PMID:34767876 methyl salicylate increases expression ISO RGD:1317959 6480464 methyl salicylate results in increased expression of AKR1B10 mRNA CTD PMID:20566472 methylisothiazolinone increases expression ISO RGD:1317959 6480464 2-methyl-4-isothiazolin-3-one results in increased expression of AKR1B10 mRNA CTD PMID:30806763 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal increases expression ISO RGD:1317959 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased expression of AKR1B10 mRNA CTD PMID:21215737 N-methyl-N-nitrosourea increases expression ISO RGD:1317960 6480464 Methylnitrosourea results in increased expression of AKR1B10 mRNA CTD PMID:25270620 N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with 2-Acetylaminofluorene] results in increased expression of AKR1B10 mRNA CTD PMID:14656948 N-Nitrosopyrrolidine increases expression ISO RGD:1317959 6480464 N-Nitrosopyrrolidine results in increased expression of AKR1B10 mRNA CTD PMID:32234424 NADP zwitterion multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 , PMID:21910479 NADP zwitterion increases activity ISO RGD:1317959 6480464 NADP results in increased activity of AKR1B10 protein CTD PMID:23295224 NADP zwitterion affects binding ISO RGD:1317959 6480464 NADP binds to AKR1B10 protein mutant form binds to fidarestat CTD PMID:23295227 NADP zwitterion decreases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in decreased reduction of NADP CTD PMID:19013440 NADP(+) multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein co-treated with NADP] affects the reduction of Glyceraldehyde more ... CTD PMID:17329238 , PMID:21910479 NADP(+) increases activity ISO RGD:1317959 6480464 NADP results in increased activity of AKR1B10 protein CTD PMID:23295224 NADP(+) affects binding ISO RGD:1317959 6480464 NADP binds to AKR1B10 protein mutant form binds to fidarestat CTD PMID:23295227 NADP(+) decreases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in decreased reduction of NADP CTD PMID:19013440 naphthalenes multiple interactions ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of and affects the activity of Naphthalenes CTD PMID:21910479 nickel atom increases expression ISO RGD:1317959 6480464 Nickel results in increased expression of AKR1B10 mRNA CTD PMID:25583101 nickel sulfate increases expression ISO RGD:1317959 6480464 nickel sulfate results in increased expression of AKR1B10 mRNA CTD PMID:20566472 nitrososulfamethoxazole increases expression ISO RGD:1317959 6480464 4-nitrososulfamethoxazole results in increased expression of AKR1B10 mRNA CTD PMID:28444390 O-methyleugenol increases expression ISO RGD:1317959 6480464 methyleugenol results in increased expression of AKR1B10 mRNA CTD PMID:32234424 ochratoxin A decreases expression EXP 6480464 ochratoxin A results in decreased expression of AKR1B10 mRNA CTD PMID:18417182 ochratoxin A decreases expression ISO RGD:1317959 6480464 ochratoxin A results in decreased expression of AKR1B10 mRNA CTD PMID:32905824 oleanolic acid multiple interactions ISO RGD:1317959 6480464 Oleanolic Acid inhibits the reaction [[AKR1B10 protein results in decreased susceptibility to Doxorubicin] which results in increased expression of MMP2 mRNA] more ... CTD PMID:25686905 , PMID:27417252 p-chloromercuribenzenesulfonic acid decreases activity ISO RGD:1317959 6480464 4-Chloromercuribenzenesulfonate results in decreased activity of AKR1B10 protein CTD PMID:23261715 para-Cresidine increases expression ISO RGD:1317959 6480464 cresidine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 paracetamol decreases expression ISO RGD:1317959 6480464 Acetaminophen results in decreased expression of AKR1B10 mRNA CTD PMID:21420995 , PMID:29067470 paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of AKR1B10 mRNA CTD PMID:33387578 paraquat increases expression ISO RGD:1317959 6480464 Paraquat results in increased expression of AKR1B10 mRNA CTD PMID:35182771 pazopanib multiple interactions ISO RGD:1317959 6480464 pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] CTD PMID:29356861 pentane-2,3-dione multiple interactions ISO RGD:1317959 6480464 [AKR1B10 protein results in increased reduction of 2, 3-pentanedione] which results in increased chemical synthesis of Pentanones CTD PMID:23295224 pentane-2,3-dione increases reduction ISO RGD:1317959 6480464 AKR1B10 protein results in increased reduction of 2, 3-pentanedione CTD PMID:23295224 perfluorooctane-1-sulfonic acid increases expression ISO RGD:1317959 6480464 perfluorooctane sulfonic acid results in increased expression of AKR1B10 mRNA CTD PMID:27153767 perfluorooctanoic acid increases expression ISO RGD:1317959 6480464 perfluorooctanoic acid results in increased expression of AKR1B10 mRNA, perfluorooctanoic acid results in increased expression of AKR1B10 protein CTD PMID:26879310 , PMID:27153767 phenethyl caffeate decreases activity ISO RGD:1317959 6480464 caffeic acid phenethyl ester results in decreased activity of AKR1B10 protein CTD PMID:27163852 phenobarbital affects expression ISO RGD:1317959 6480464 Phenobarbital affects the expression of AKR1B10 mRNA CTD PMID:19084549 phenol increases expression ISO RGD:1317959 6480464 Phenol results in increased expression of AKR1B10 mRNA CTD PMID:26198647 phenylmercury acetate increases expression ISO RGD:1317959 6480464 Phenylmercuric Acetate results in increased expression of AKR1B10 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO RGD:1317959 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1B10 mRNA CTD PMID:27188386 phorbol 13-acetate 12-myristate multiple interactions ISO RGD:1317959 6480464 [Tetradecanoylphorbol Acetate results in increased expression of JUN mRNA] which results in decreased expression of AKR1B10 mRNA, U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased expression of AKR1B10 mRNA] CTD PMID:25463304 phorbol 13-acetate 12-myristate decreases expression ISO RGD:1317959 6480464 Tetradecanoylphorbol Acetate results in decreased expression of AKR1B10 mRNA, Tetradecanoylphorbol Acetate results in decreased expression of AKR1B10 protein CTD PMID:25463304 , PMID:26198647 picoxystrobin decreases expression ISO RGD:1317959 6480464 picoxystrobin results in decreased expression of AKR1B10 mRNA CTD PMID:33512557 pimecrolimus multiple interactions ISO RGD:1317959 6480464 pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] CTD PMID:29356861 pirinixic acid multiple interactions ISO RGD:1317959 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of AKR1B10 mRNA more ... CTD PMID:19028477 , PMID:19710929 pirinixic acid multiple interactions ISO RGD:1317960 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of AKR1B10 mRNA CTD PMID:19710929 pirinixic acid increases expression ISO RGD:1317959 6480464 pirinixic acid results in increased expression of AKR1B10 mRNA CTD PMID:26198647 pirinixic acid decreases activity ISO RGD:1317959 6480464 pirinixic acid results in decreased activity of AKR1B10 protein, pirinixic acid results in decreased activity of AKR1B10 protein mutant form CTD PMID:18325492 potassium bromate multiple interactions ISO RGD:1317960 6480464 [potassium bromate co-treated with bisphenol A] affects the expression of AKR1B10 mRNA more ... CTD PMID:27082013 potassium bromate affects expression ISO RGD:1317960 6480464 potassium bromate affects the expression of AKR1B10 mRNA CTD PMID:27082013 progesterone multiple interactions ISO RGD:1317959 6480464 [Progesterone co-treated with Estradiol] results in decreased expression of AKR1B10 mRNA CTD PMID:17404688 progesterone decreases expression ISO RGD:1317959 6480464 Progesterone results in decreased expression of AKR1B10 mRNA CTD PMID:17404688 propan-2-ol increases expression ISO RGD:1317959 6480464 2-Propanol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 propiconazole multiple interactions ISO RGD:1317959 6480464 [propiconazole co-treated with tebuconazole] results in increased expression of AKR1B10 mRNA CTD PMID:30989312 propiconazole increases expression ISO RGD:1317959 6480464 propiconazole results in increased expression of AKR1B10 mRNA CTD PMID:30989312 quercetin decreases expression ISO RGD:1317959 6480464 Quercetin results in decreased expression of AKR1B10 mRNA CTD PMID:21632981 quercetin increases expression ISO RGD:1317959 6480464 Quercetin results in increased expression of AKR1B10 mRNA CTD PMID:34767876 quinolin-8-ol increases expression ISO RGD:1317959 6480464 Oxyquinoline results in increased expression of AKR1B10 mRNA CTD PMID:21632981 , PMID:26198647 rac-lactic acid increases expression ISO RGD:1317959 6480464 Lactic Acid results in increased expression of AKR1B10 mRNA CTD PMID:20566472 rac-lactic acid decreases expression ISO RGD:1317959 6480464 Lactic Acid results in decreased expression of AKR1B10 mRNA CTD PMID:30851411 reserpine increases expression ISO RGD:1317959 6480464 Reserpine results in increased expression of AKR1B10 mRNA CTD PMID:26198647 resorcinol increases expression ISO RGD:1317959 6480464 resorcinol results in increased expression of AKR1B10 mRNA CTD PMID:22623647 more ... resveratrol multiple interactions ISO RGD:1317960 6480464 [resveratrol co-treated with HMGB1 protein] results in increased expression of AKR1B10 mRNA CTD PMID:25979658 rifampicin increases expression ISO RGD:1317959 6480464 Rifampin results in increased expression of AKR1B10 mRNA CTD PMID:29356861 rifampicin multiple interactions ISO RGD:1317959 6480464 pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA], pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA] CTD PMID:29356861 rotenone decreases expression ISO RGD:1317959 6480464 Rotenone results in decreased expression of AKR1B10 mRNA CTD PMID:33512557 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO RGD:1317959 6480464 [S-(1 more ... CTD PMID:35811015 S-(1,2-dichlorovinyl)-L-cysteine increases expression ISO RGD:1317959 6480464 S-(1, 2-dichlorovinyl)cysteine results in increased expression of AKR1B10 mRNA CTD PMID:35811015 SB 431542 multiple interactions ISO RGD:1317959 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of AKR1B10 mRNA CTD PMID:27188386 silicon dioxide decreases expression ISO RGD:1317959 6480464 Silicon Dioxide analog results in decreased expression of AKR1B10 mRNA CTD PMID:25895662 silicon dioxide decreases expression ISO RGD:1317960 6480464 Silicon Dioxide results in decreased expression of AKR1B10 mRNA CTD PMID:19073995 silicon dioxide increases secretion ISO RGD:1317959 6480464 Silicon Dioxide analog results in increased secretion of AKR1B10 protein CTD PMID:25895662 silver atom increases expression ISO RGD:1317959 6480464 Silver results in increased expression of AKR1B10 mRNA CTD PMID:26014281 silver(0) increases expression ISO RGD:1317959 6480464 Silver results in increased expression of AKR1B10 mRNA CTD PMID:26014281 sodium arsenate multiple interactions ISO RGD:1317959 6480464 [sodium arsenate results in increased abundance of Arsenic] which results in increased expression of AKR1B10 mRNA CTD PMID:32525701 sodium arsenite increases expression ISO RGD:1317959 6480464 sodium arsenite results in increased expression of AKR1B10 mRNA CTD PMID:23876855 more ... sodium arsenite multiple interactions ISO RGD:1317959 6480464 [sodium arsenite results in increased abundance of arsenite] which results in increased expression of AKR1B10 mRNA CTD PMID:32076005 sodium dodecyl sulfate increases expression ISO RGD:1317959 6480464 Sodium Dodecyl Sulfate results in increased expression of AKR1B10 mRNA CTD PMID:20566472 , PMID:30806763 sorbinil multiple interactions ISO RGD:1317959 6480464 sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Daunorubicin], sorbinil inhibits the reaction [AKR1B10 protein results in increased reduction of Glyceraldehyde] CTD PMID:19028477 sorbinil decreases activity ISO RGD:1317959 6480464 sorbinil results in decreased activity of AKR1B10 protein CTD PMID:18325492 sulforaphane increases expression ISO RGD:1317959 6480464 sulforaphane results in increased expression of AKR1B10 mRNA CTD PMID:24383545 more ... sulindac multiple interactions ISO RGD:1317959 6480464 Sulindac analog binds to and results in decreased activity of AKR1B10 protein, Sulindac binds to and results in decreased activity of AKR1B10 protein CTD PMID:25532697 sulindac sulfone multiple interactions ISO RGD:1317959 6480464 sulindac sulfone binds to and results in decreased activity of AKR1B10 protein CTD PMID:25532697 tebuconazole increases expression ISO RGD:1317959 6480464 tebuconazole results in increased expression of AKR1B10 mRNA CTD PMID:30989312 tebuconazole multiple interactions ISO RGD:1317959 6480464 [propiconazole co-treated with tebuconazole] results in increased expression of AKR1B10 mRNA CTD PMID:30989312 temozolomide decreases expression ISO RGD:1317959 6480464 Temozolomide results in decreased expression of AKR1B10 mRNA CTD PMID:31758290 tert-butyl hydroperoxide increases expression ISO RGD:1317959 6480464 tert-Butylhydroperoxide results in increased expression of AKR1B10 mRNA CTD PMID:23410634 , PMID:34767876 tetraphene increases expression ISO RGD:1317959 6480464 benz(a)anthracene results in increased expression of AKR1B10 mRNA CTD PMID:22236718 thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of AKR1B10 mRNA CTD PMID:23411599 , PMID:34492290 titanium dioxide decreases phosphorylation ISO RGD:1317959 6480464 titanium dioxide results in decreased phosphorylation of AKR1B10 protein CTD PMID:21439344 trans-isoeugenol increases expression ISO RGD:1317959 6480464 isoeugenol results in increased expression of AKR1B10 mRNA CTD PMID:20566472 Tributyltin oxide increases expression ISO RGD:1317959 6480464 bis(tri-n-butyltin)oxide results in increased expression of AKR1B10 mRNA CTD PMID:26198647 trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of AKR1B10 mRNA CTD PMID:33387578 Triptolide decreases expression EXP 6480464 triptolide results in decreased expression of AKR1B10 protein CTD PMID:32519852 troglitazone increases expression ISO RGD:1317959 6480464 troglitazone results in increased expression of AKR1B10 mRNA CTD PMID:25572481 urethane decreases expression ISO RGD:1317959 6480464 Urethane results in decreased expression of AKR1B10 mRNA CTD PMID:28818685 valproic acid decreases expression ISO RGD:1317959 6480464 Valproic Acid results in decreased expression of AKR1B10 mRNA CTD PMID:29154799 valproic acid affects expression ISO RGD:1317959 6480464 Valproic Acid affects the expression of AKR1B10 mRNA CTD PMID:25979313 vitamin E increases expression ISO RGD:1317959 6480464 Vitamin E results in increased expression of AKR1B10 mRNA CTD PMID:34767876
